



## Corporate Profile

CytomX Therapeutics develops Probody™ therapeutics for the treatment of cancer. Probody therapeutics are fully recombinant masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. The Probody approach is designed to blunt systemic toxicities associated with antibodies and expand the therapeutic window of these drugs, potentially unlocking new therapeutic targets. The Company is initially focusing this highly innovative platform to discover and develop new immunotherapy and antibody drug conjugate therapies to treat areas of major unmet medical need in oncology.

## Stock Performance

### CTMX (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	<b>\$14.75</b>
Change (%)	<b>▲ 0.86 (6.19%)</b>
Volume	49,673
52 Week Low	\$9.87
Market Cap	\$512,087,728
Rolling EPS	-1.70
PE Ratio	0
Shares Outstanding	36,867,367

Data as of 08/22/17 1:19 p.m. ET



## Recent Headlines

08/10/17

CytomX to Present at the 2017 Wedbush PacGrow Healthcare Conference

08/07/17

CytomX Announces Second Quarter 2017 Financial Results and Mid-Year Update Webcast Conference Call

07/27/17

CytomX Therapeutics to Announce Second Quarter 2017 Financial Results and Provide Mid-Year Update

## Upcoming Events

There are currently no events scheduled.

## SEC Filings

Filing Date	Form	Description
08/11/17	4	Statement of changes in beneficial ownership of securities
08/11/17	4	Statement of changes in beneficial ownership of securities
08/07/17	10-Q	Quarterly report which provides a continuing view of a company's financial position
08/07/17	8-K	Report of unscheduled material events or corporate event

Data provided by Nasdaq. Minimum 15 minutes delayed.